Do you want to read an article? Please log in or register.
An overview of biosimilars and non-biologic complex drugs in Europe, the United States, and Canada and their relevance to multiple sclerosis
Multiple Sclerosis
Related content
SPECIAL REPORT
Multiple Sclerosis
Vaccination Readiness in Multiple Sclerosis
RECOMMENDED
Multiple Sclerosis
Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis
Drug Saf.
Soleimani B, Murray K, Hunt D
doi: 10.1007/s40264-019-
Multiple Sclerosis
Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis
Cochrane Database Syst Rev.
Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G
doi: 10.1002/
Multiple Sclerosis
Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis
Brain.
Amato MP, Fonderico M, Portaccio E, Pastò L, Razzolini L, Prestipino E, Bellinvia A, Tudisco L, Fratangelo R, Comi G, Patti F, De Luca G, Brescia Morra V, Cocco E, Pozzilli C, Sola P, Bergamaschi R, Salemi G, Inglese M, Millefiorini E, Galgani S, Zaffaroni M, Ghezzi A, Salvetti M, Lus G, Florio C, Totaro R, Granella F, Vianello M, Gatto M, Di Battista G, Aguglia U, Logullo FO, Simone M, Lucisano G, Iaffaldano P, Trojano M
doi: 10.1093/brain/awaa251.
Multiple Sclerosis
Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study.
J Neurol.
Kamm CP, Barin L, Gobbi C, Pot C, Calabrese P, Salmen A, Achtnichts L, Kesselring J, Puhan MA, von Wyl V, Swiss Multiple Sclerosis Registry (SMSR).
doi: 10.1007/s00415-019-09563-y.
RECOMMENDED
Multiple Sclerosis
Comparison of rituximab originator (MabThera®) to biosimilar (Truxima®) in patients with multiple sclerosis
★ 2
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Mult Scler.
Perez T, Rico A, Boutière C, Maarouf A, Roudot M, Honoré S, Pelletier J, Bertault-Peres P, Audoin B
doi: 10.1177/1352458520912170.
Multiple Sclerosis
A roadmap to precision medicine for multiple sclerosis
Mult Scler.
Chitnis T, Prat A
doi: 10.1177/1352458519881558.
Multiple Sclerosis
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)
Ther Adv Neurol Disord
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Kallmann B, Kleinschnitz C, Klotz L, Leussink VI, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F, ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG).
doi: 10.1177/17562864211039648
RECOMMENDED
Multiple Sclerosis
Advances in oral immunomodulating therapies in relapsing multiple sclerosis
★ 3
Recommended by
Prof. Dr Christian Kamm, Faculty Member
★ 2
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Lancet Neurol.
Derfuss T, Mehling M, Papadopoulou A, Bar-Or A, Cohen JA, Kappos L
doi: 10.1016/S1474-4422(19)30391-6.